Should sodium-glucose cotransporter-2 inhibitors be first-line treatment for patients with type 2 diabetes?

See related article at [www.cmaj.ca/lookup/doi/10.1503/cmaj.191283][1] KEY POINTS The treatment landscape for type 2 diabetes has expanded extensively over the last few decades. Previously, the only decision required of physicians initiating oral pharmacotherapy for type 2 diabetes was to choose